Journal Article Summary
The article investigates the effectiveness of risperidone, an antipsychotic medication, as an additional treatment for patients suffering from difficult-to-treat unipolar, non-psychotic major depression. This topic is significant because a substantial number of individuals with major depression do not respond adequately to standard antidepressant therapies, leaving them with persistent symptoms and a reduced quality of life. By exploring the potential benefits of risperidone as an augmenting agent, the study aims to provide insights into alternative treatment options for these patients.
In this study, 97 patients who had not responded to antidepressant monotherapy were randomly assigned to receive either risperidone or a placebo for four weeks. The primary goal was to measure remission rates using the Montgomery–Asberg Depression Rating Scale, while secondary outcomes included other depression severity scales and quality of life assessments. The results indicated that 52% of patients receiving risperidone achieved remission compared to 24% in the placebo group, suggesting that risperidone significantly enhances the likelihood of recovery. Additionally, those on risperidone reported better improvements in their quality of life, although there was a notable increase in weight gain among this group.
Despite these promising findings, the study has limitations, including a relatively short duration and a small sample size, which may affect the generalizability of the results. Patients should be aware of the potential side effects, such as weight gain, when considering risperidone as part of their treatment plan. It is essential for individuals experiencing difficult-to-treat depression to discuss these findings and any concerns with their healthcare provider to determine the best course of action tailored to their specific needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Keitner Gabor I., Garlow Steven J., Ryan Christine E., Ninan Philip T., Solomon David A., Nemeroff Charles B., Keller Martin B.. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. Journal of psychiatric research 2008. DOI: 10.1016/j.jpsychires.2008.05.003. PMID: 18586273. PMCID: PMC3685867.
Featured Pill Pals Product
Risperidone 0.25 mg Tablets --- Generic For Risperdal --- Ajanta
Risperidone 0.25 mg Tablets — Generic For Risperdal — Ajanta is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
